Is Lupin the Best Stock in Its Sector? A Look at the Numbers
- October 12, 2026
- Posted by: Neeraj Pandey
- Category: Market
Lupin CMP Rs 1,959 (12 Oct 2026). Market cap Rs 89,629 Cr. ROE 23.76%. P/E 16.15x versus Industry P/E 36.69x.
Quick Answer
Lupin is one of the names investors compare when screening the Healthcare sector, built on a 23.76% return on equity and a P/E of 16.15x against an Industry P/E of 36.69x. Whether Lupin is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.
Is Lupin the best stock in its sector? The stock trades on the NSE at Rs 1,959 as of 12 October 2026, within its 52-week range of Rs 1,900.00 to Rs 2,529.50. Lupin Ltd, based in Mumbai, is a global pharmaceutical company that makes and sells branded and generic formulations, biotechnology products and APIs across India, the US and other markets.
Lupin sits in the Healthcare sector, and its 23.76% ROE and 16.15x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Lupin
Lupin Ltd, based in Mumbai, is a global pharmaceutical company that makes and sells branded and generic formulations, biotechnology products and APIs across India, the US and other markets. It is one of the larger Indian pharma companies by revenue and is known for its respiratory and complex generics presence. The stock trades about 23 percent below its 52-week high and about 3 percent above its 52-week low. At a market capitalisation of Rs 89,629 Cr, it is tracked as part of the Healthcare sector on Univest.
Is Lupin the Best Stock in Its Sector?
Lupin makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 23.76% ROE with a 16.15x P/E against the sector’s 36.69x Industry P/E. Lupin’s 16.15x P/E is far below the 36.69x Industry P/E and is backed by a 23.76% ROE and a 0.29 debt to equity ratio, though regulated market pricing and approvals can move earnings.
| Metric | Lupin |
|---|---|
| CMP (NSE) | Rs 1,958.90 |
| 52-Week High / Low | Rs 2,529.50 / Rs 1,900.00 |
| Market Cap | Rs 89,629 Cr |
| P/E (TTM) vs Industry P/E | 16.15x vs 36.69x |
| P/B | 3.99 |
| ROE | 23.76% |
| EPS (TTM) | Rs 121.39 |
| Dividend Yield | 0.92% |
| Debt to Equity | 0.29 |
Compare Lupin Against Other Healthcare Sector Stocks
How Lupin Compares Against Its Healthcare Sector Peers
The table below sets Lupin against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Lupin | 89,629 | 16.15 | 23.76% | 0.29 |
| Zydus Lifesciences | 1,11,232 | 24.22 | 18.59% | 0.46 |
| Alkem Laboratories | 62,954 | 28.56 | 16.66% | 0.15 |
| Peer average (2 companies) | – | 26.39 | 17.62% | 0.30 |
Against this peer set, Lupin’s 23.76% ROE is above the 17.62% peer average, and its P/E of 16.15x runs below the peer average of 26.39x. Lupin’s 16.15x P/E is far below the 36.69x Industry P/E and is backed by a 23.76% ROE and a 0.29 debt to equity ratio, though regulated market pricing and approvals can move earnings.
What Makes Lupin Worth Watching in Healthcare
- Large valuation gap: A 16.15x P/E against a 36.69x Industry P/E is a wide discount to the benchmark.
- Strong returns: A 23.76% ROE is high for a pharma manufacturer.
- Low leverage: A debt to equity ratio of 0.29 keeps the balance sheet comfortable.
Lupin Valuation: Is It Justified?
Lupin’s 16.15x P/E is far below the 36.69x Industry P/E and is backed by a 23.76% ROE and a 0.29 debt to equity ratio, though regulated market pricing and approvals can move earnings. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is VIP Clothing the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Lupin and other Healthcare sector stocks.
How to Track Lupin Before You Invest
Before deciding whether Lupin deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.
- Open the Univest Screener and search for Lupin to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
- Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Lupin earns a place in the best stock in its sector conversation on the strength of a 23.76% ROE and a P/E of 16.15x against a 36.69x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Lupin the best stock in its sector?
Ans. Lupin has a 23.76% ROE and trades at 16.15x P/E against a 36.69x Industry P/E, and compares above the peer average ROE of 17.62% in this article’s named comparison, so the answer depends on what an investor is prioritising.
What is the current share price of Lupin?
Ans. Lupin was trading at Rs 1,958.90 on the NSE as of 12 October 2026, within its 52-week range of Rs 1,900.00 to Rs 2,529.50.
What sector does Lupin belong to?
Ans. Lupin is classified under the Healthcare sector on Univest.
How does Lupin compare to its sector peers on P/E?
Ans. Lupin’s P/E of 16.15x is below the 26.39x average of the 2 named peers compared in this article.
What is Lupin’s return on equity?
Ans. Lupin reported a return on equity of 23.76%, which is above the 17.62% average of its named peers in this comparison.
Should I invest in Lupin based on its sector position?
Ans. Lupin’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.
{“@context”: “https://schema.org”, “@type”: “FAQPage”, “mainEntity”: [{“@type”: “Question”, “name”: “Is Lupin the best stock in its sector?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Lupin has a 23.76% ROE and trades at 16.15x P/E against a 36.69x Industry P/E, and compares above the peer average ROE of 17.62% in this article’s named comparison, so the answer depends on what an investor is prioritising.”}}, {“@type”: “Question”, “name”: “What is the current share price of Lupin?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Lupin was trading at Rs 1,958.90 on the NSE as of 12 October 2026, within its 52-week range of Rs 1,900.00 to Rs 2,529.50.”}}, {“@type”: “Question”, “name”: “What sector does Lupin belong to?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Lupin is classified under the Healthcare sector on Univest.”}}, {“@type”: “Question”, “name”: “How does Lupin compare to its sector peers on P/E?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Lupin’s P/E of 16.15x is below the 26.39x average of the 2 named peers compared in this article.”}}, {“@type”: “Question”, “name”: “What is Lupin’s return on equity?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Lupin reported a return on equity of 23.76%, which is above the 17.62% average of its named peers in this comparison.”}}, {“@type”: “Question”, “name”: “Should I invest in Lupin based on its sector position?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Lupin’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.”}}]}
